Patient-Centric & Prospective Medicine Project

The Center for Medicine in the Public Interest (CMPI) has initiated a research program to study the treatment preferences of patients with Idiopathic pulmonary fibrosis (IPF). The project is supported by Intermune, a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. Dr. John F P Bridges PhD, an Associate Professor at the Johns Hopkins Bloomberg School of Public Health and Senior Fellow at CMPI, will serve as the principal investigator of this project. The project will apply the principles of community-based participatory medicine to engage patients, family members, providers and other stakeholder in the design and pilot of a survey instrument to measure the stated-preferences of patients of with IPF for the potential benefits and risk of therapy. A geographically diverse sample of patients with IPF will be then recruited through clinics and advocacy groups to complete the survey. Analysis will use state-of-the-art methods to estimate preferences and results will be disseminated widely.
Sign Up for Our Email Newsletter

RECENT NEWS

Trump's Plan To Bring Down Drug Prices Is Winner

Trump's Plan To Bring Down Drug Prices Is Winner

President Trump just rolled out his "American Patients First" strategy to bring down drug prices. ...  Read more

More Generics Aren't A Prescription Drug Cost Silver Bullet

More Generics Aren't A Prescription Drug Cost Silver Bullet

Are more generic prescription drugs the answer to the prescription drug affordability crisis?...  Read more

'It's the health care ecosystem, Stupid'

'It's the health care ecosystem, Stupid'

It’s high time we focused on the questionable practices of Pharmacy Benefit Managers....  Read more

DRUGWONKS BLOG